Agios Pharmaceuticals AGIO Income Statement (2012-2026)

NASDAQ AGIO
$33.21 +0.08 (+0.24%)
As of: Sep 4, 2026 · 12:50 PM EDT
Reported Financials

Agios Pharmaceuticals Quarterly Income Statement

Periods 57 quarters
Latest Jun 2026

Agios Pharmaceuticals reported revenue of $44.74M and net income of -$100.70M for the quarter ended Jun 2026, up 259.3% year over year. This income statement covers 57 quarters of results from Jun 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
54.72M54.33M54.78M54.82M54.89M55.04M55.54M55.73M55.88M55.95M56.75M56.88M57.02M57.16M57.89M58.04M58.28M58.45M59.34M59.60M
Revenue & cost
Revenue
0.83M5.58M3.52M4.31M5.61M6.71M7.40M7.10M8.19M8.62M8.96M10.73M8.73M12.46M12.88M19.97M20.75M44.74M
Gross Profit
0.49M5.15M3.00M3.90M5.05M5.60M6.77M6.52M7.56M7.12M8.18M9.47M7.64M10.75M11.20M18.09M19.43M41.75M
Operating items
Research & DevelopmentR&D
64.00M73.30M70.12M74.52M64.97M70.30M67.30M68.89M81.84M77.49M68.62M77.40M72.45M82.81M72.74M91.94M86.80M88.06M81.15M100.75M
Selling, General & AdministrativeSG&A
27.15M31.53M31.52M28.26M29.12M32.77M28.37M30.41M25.82M35.30M31.01M35.54M38.54M51.70M41.53M45.87M41.27M51.61M48.30M51.55M
Other Operating ExpensesOther Opex
2.00M2.64M2.97M2.70M4.44M-9.90M0.55M1.11M0.63M1.50M200.00M1.08M1.70M1.32M3.00M
Operating ExpensesOpex
91.15M104.83M101.98M103.22M94.61M103.48M96.22M100.41M108.30M113.38M100.26M114.43M111.78M135.77M115.36M139.51M129.75M141.54M130.77M155.30M
Operating IncomeOp. Inc
-91.15M-104.83M-101.14M-97.64M-91.09M-99.17M-90.61M-93.70M-100.90M-106.28M-92.07M-105.82M-102.81M-125.04M-106.63M-127.06M-116.87M-121.58M-110.03M-110.55M
EBIT
-91.15M-104.83M-101.14M-97.64M-91.09M-99.17M-90.61M-93.70M-100.90M-106.28M-92.07M-105.82M-102.81M-125.04M-106.63M-127.06M-116.87M-121.58M-110.03M-110.55M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.26M0.33M0.69M1.79M3.82M6.49M8.09M8.25M8.38M8.62M8.89M8.12M13.06M18.02M16.09M14.51M13.37M12.41M10.79M9.73M
Other Non Operating IncomeOther Non Op Inc.
4.64M3.27M2.97M1.34M1.08M1.36M1.50M1.64M1.20M1.71M1.63M1.58M1.65M1.62M1.25M0.52M0.07M0.11M0.12M0.12M
Net income details
EBT
-84.26M-98.58M-100.45M-95.85M-87.27M-92.68M-82.52M-85.45M-91.32M-95.94M-83.18M-97.70M1,001.03M-105.40M-90.54M-112.54M-103.43M-109.06M-99.23M-100.82M
Tax ProvisionsTaxes
53.12M-8.88M-1.02M
Profit After TaxPAT
-88.77M-94.63M-94.77M-91.81M-81.75M36.53M-81.02M-83.81M-91.32M-95.94M-81.55M-96.12M947.91M-96.52M-89.29M-112.02M-103.43M-108.04M-99.11M-100.70M
Income from Continuing OperationsIncome (Continuing)
-84.26M-98.58M-100.45M-95.85M-87.27M-92.68M-82.52M-85.45M-91.32M-95.94M-83.18M-97.70M947.91M-96.52M-90.54M-112.54M-103.43M-108.04M-99.23M-100.82M
Income from Discontinued OperationsIncome (Discontinued)
-4.51M3.96M
Consolidated Net IncomeConsol Net Inc.
-88.77M-94.63M-100.45M-95.85M-87.27M-92.68M-82.52M-85.45M-91.32M-95.94M-83.18M-97.70M947.91M-96.52M-90.54M-112.54M-103.43M-108.04M-99.23M-100.82M
Income towards Parent CompanyParent Net Inc
-88.77M-94.63M-100.45M-95.85M-87.27M-92.68M-82.52M-85.45M-91.32M-95.94M-83.18M-97.70M947.91M-96.52M-90.54M-112.54M-103.43M-108.04M-99.23M-100.82M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-88.77M-94.63M-100.45M-95.85M-87.27M-92.68M-82.52M-85.45M-91.32M-95.94M-83.18M-97.70M947.91M-96.52M-90.54M-112.54M-103.43M-108.04M-99.23M-100.82M
Additional items
EPS (Basic)
-1.56-1.57-1.84-1.75-1.59-1.69-1.49-1.54-1.64-1.72-1.48-1.7216.65-1.70-1.58-1.94-1.78-1.86-1.69-1.69
EPS (Diluted)
-1.56-1.57-1.84-1.75-1.59-1.69-1.49-1.54-1.64-1.72-1.48-1.7216.22-1.67-1.58-1.94-1.78-1.86-1.69-1.69
Shares Outstanding
57.05M60.45M54.56M54.80M54.84M54.79M55.27M55.60M55.80M55.65M56.38M56.80M56.94M56.81M57.46M57.93M58.14M57.97M58.78M59.49M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
57.05M60.45M54.56M54.80M54.84M54.79M55.27M55.60M55.80M55.65M56.38M56.80M58.43M57.89M57.46M57.93M58.14M57.97M58.78M59.49M
EBITDA
-91.15M-104.83M-101.14M-97.64M-91.09M-99.17M-90.61M-93.70M-100.90M-106.28M-92.07M-105.82M-102.81M-125.04M-106.63M-127.06M-116.87M-121.58M-110.03M-110.55M
Tax Rate
5.318.420.93